Chimeric antigen receptor-modified T cells in acute lymphoblastic leukemia

Recent studies have documented the ability of chimeric antigen receptor-modified autologous T cells targeting the CD19 antigen on B cells to induce rapid and deep remissions in adult and pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).^1,2

*Click on the links to the left for PDFs of the full article and related Commentary.
 

Recent studies have documented the ability of chimeric antigen receptor-modified autologous T cells targeting the CD19 antigen on B cells to induce rapid and deep remissions in adult and pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).^1,2

*Click on the links to the left for PDFs of the full article and related Commentary.
 

Recent studies have documented the ability of chimeric antigen receptor-modified autologous T cells targeting the CD19 antigen on B cells to induce rapid and deep remissions in adult and pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).^1,2

*Click on the links to the left for PDFs of the full article and related Commentary.